Studies conducted in a rat model of thyroid cancer showed that delivery of IL-12 gene with adenovirus (AdIL-12) was efficacious to elicit systemic anti-tumor immunity, unlike treatment with AdGM-CSF with cells expressing IL-12 or GM–CSF, which elicited only local effects. This evidence concerns the gene CSF2 and thyroid cancer.